Recruiting
Registered drug
A Study of SAB-142 to Slow the Progression of Type 1 Diabetes in Adults and Children Recently Diagnosed with the Disease
Registered drug
- Substances:–
Countries:
Austria
Austria- Participants:0–17 years · 18–64 years
Find therapies in clinical trials near you – page 77
- recruiting
- 3 974
- countries
- 28
- conditions
- 2 109
3 974 trials recruiting28 European countries2 109 conditions coveredUpdated today
10 386 trials match your criteria
Recruiting
Pulmonary hypertension
RecruitingTesting Treprostinil Palmitil Inhalation Powder for Improving Exercise Ability in Patients with Pulmonary Hypertension Related to Interstitial Lung Disease
Investigational
Testing Treprostinil Palmitil Inhalation Powder for Improving Exercise Ability in Patients with Pulmonary Hypertension Related to Interstitial Lung Disease
Investigational
- Disease:Pulmonary hypertension
- Substances:–
Countries:Austria
Austria- Participants:18–64 years · 65+ years
Recruiting
Cervix carcinoma
RecruitingA Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned
Registered drugNo placebo
A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned
Registered drugNo placebo
- Disease:Cervix carcinoma
- Substances:–
Countries:Austria
Austria- Participants:18–64 years · 65+ years
Recruiting
Ovarian cancer
RecruitingA Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein
InvestigationalNo placebo
A Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein
InvestigationalNo placebo
- Disease:Ovarian cancer
- Substances:INCB123667
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:INCB123667
Recruiting
Inflammatory bowel disease
RecruitingStudy Using Fluorescent Adalimumab and Risankizumab to See How These Drugs Work in Patients with Inflammatory Bowel Disease
Registered drugNo placebo
Study Using Fluorescent Adalimumab and Risankizumab to See How These Drugs Work in Patients with Inflammatory Bowel Disease
Registered drugNo placebo
- Disease:Inflammatory bowel disease
- Substances:Adalimumab
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Adalimumab
Recruiting
Crohn's disease
RecruitingStudy of icotrokinra for adults with moderately to severely active Crohn's disease
Investigational
Study of icotrokinra for adults with moderately to severely active Crohn's disease
Investigational
- Disease:Crohn's disease
- Substances:Icotrokinra
Countries:Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Icotrokinra
Recruiting
Colitis ulcerative
RecruitingTesting icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis
Investigational
Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis
Investigational
- Disease:Colitis ulcerative
- Substances:Icotrokinra
Countries:Belgium
Belgium- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Icotrokinra
Recruiting
Colorectal cancer metastatic
RecruitingComparing irinotecan plus cetuximab with trifluridine and tipiracil plus bevacizumab for patients with metastatic colorectal cancer as third line treatment
Registered drugNo placebo
Comparing irinotecan plus cetuximab with trifluridine and tipiracil plus bevacizumab for patients with metastatic colorectal cancer as third line treatment
Registered drugNo placebo
- Disease:Colorectal cancer metastatic
- Substances:Trifluridine
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Trifluridine
Recruiting
Acute lymphocytic leukaemia recurrent+5
RecruitingA study testing AZD3632 alone or with other anticancer drugs in adults with acute leukemia or myelodysplastic syndromes with HOX gene overexpression
InvestigationalNo placebo
A study testing AZD3632 alone or with other anticancer drugs in adults with acute leukemia or myelodysplastic syndromes with HOX gene overexpression
InvestigationalNo placebo
- Disease:Acute lymphocytic leukaemia recurrentAcute myeloid leukaemia refractory+4
- Substances:AZD3632
Countries:
Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:AZD3632
Recruiting
Non-small cell lung cancer
RecruitingTesting zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery
Registered drugNo placebo
Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:Zongertinib
Countries:Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Zongertinib
Recruiting
Sickle cell disease
RecruitingA study testing gene therapy with DREAM01 and imatinib for patients with severe sickle cell disease to improve red blood cell production
Registered drugNo placebo
A study testing gene therapy with DREAM01 and imatinib for patients with severe sickle cell disease to improve red blood cell production
Registered drugNo placebo
- Disease:Sickle cell disease
- Substances:Imatinib
Countries:
France
France- Participants:0–17 years · 18–64 years
- Substances:Imatinib
Recruiting
Breast cancer metastatic
RecruitingA Study of Evorpacept Combined with Trastuzumab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer
Registered drugNo placebo
A Study of Evorpacept Combined with Trastuzumab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer
Registered drugNo placebo
- Disease:Breast cancer metastatic
- Substances:–
Countries:France
France- Participants:18–64 years · 65+ years